Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV (hepatitis C virus) effects and can reduce the infectivity of HCV (hepatitis C virus). Mipomersen sodium may be utilized in the research/study of homozygous familial hypercholesterolemia (HoFH).

Physicochemical Properties

CAS #	629167-92-6
Related CAS #	Mipomersen;1000120-98-8
Appearance	White to off-white solid powder
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro

Apolipoprotein (apo) B is a large amphipathic protein that plays an important role in the functioning of human lipoproteins. Mipomersen is primarily distributed in the liver and reduces the production of apoB-100, the main structural protein of atherogenic lipoproteins, including low-density lipoprotein (LDL). This lowers heart disease LDL-cholesterol and apoB-100 concentrations. Additionally, ApoB-100 binds to the LDL receptor and facilitates the endocytosis of LDL [2].

References

[1]. Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93. [2]. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs. 2011 Feb;20(2):265-72.

Solubility Data

Solubility (In Vitro)	H2O : ~100 mg/mL (~13.17 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 100 mg/mL (13.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.)